Similar articles

• Editorial comment on: Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.

  Porru D. Porru D. Eur Urol. 2009 Feb;55(2):480. doi: 10.1016/j.eururo.2008.06.033. Epub 2008 Jun 17. Eur Urol. 2009. PMID: 18583021 No abstract available.
• Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.

  Roehrborn CG, Kaplan SA, Jones JS, Wang JT, Bavendam T, Guan Z. Roehrborn CG, et al. Eur Urol. 2009 Feb;55(2):472-9. doi: 10.1016/j.eururo.2008.06.032. Epub 2008 Jun 17. Eur Urol. 2009. PMID: 18583022
• Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.

  Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Kaplan SA, et al. JAMA. 2006 Nov 15;296(19):2319-28. doi: 10.1001/jama.296.19.2319. JAMA. 2006. PMID: 17105794 Clinical Trial.
• Efficacy of the combination of an alpha1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction.

  Athanasopoulos A, Perimenis P. Athanasopoulos A, et al. Expert Opin Pharmacother. 2005 Nov;6(14):2429-33. doi: 10.1517/14656566.6.14.2429. Expert Opin Pharmacother. 2005. PMID: 16259574 Review.
• Tolterodine for treatment of overactive bladder.

  Kanofsky JA, Nitti VW. Kanofsky JA, et al. Urol Clin North Am. 2006 Nov;33(4):447-53, viii. doi: 10.1016/j.ucl.2006.06.004. Urol Clin North Am. 2006. PMID: 17011380 Review.